drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An intravenous antibody–drug conjugate (ADC) composed of a monoclonal antibody targeting an undisclosed tumor-associated surface antigen linked to a cytotoxic payload, likely a topoisomerase I inhibitor. Upon binding and internalization, it releases the payload to cause DNA damage and apoptosis, with potential bystander effect, in advanced solid tumors.
nci_thesaurus_concept_id
C211590
nci_thesaurus_preferred_term
Antibody-drug Conjugate PHN-010
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of an as of yet undisclosed monoclonal antibody directed against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ADC PHN-010 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Intravenous monoclonal antibody–drug conjugate that binds a tumor-associated surface antigen, is internalized, and releases a cytotoxic payload—likely a topoisomerase I inhibitor—to induce DNA damage and apoptosis, with potential bystander effect, in antigen-expressing solid tumors.
drug_name
PHN-010
nct_id_drug_ref
NCT06457997